CEO Jeff Albers has done a decent job of delivering relatively good performance at Blueprint Medicines Corporation (NASDAQ:BPMC) recently. As shareholders go into the upcoming AGM on 02 June 2021, CEO compensation will probably not be their focus, but rather the steps management will take to continue the growth momentum. Here is our take on why we think the CEO compensation looks appropriate.
Comparing Blueprint Medicines Corporation's CEO Compensation With the industry
Our data indicates that Blueprint Medicines Corporation has a market capitalization of US$5.6b, and total annual CEO compensation was reported as US$6.3m for the year to December 2020. That's a notable decrease of 32% on last year. While we always look at total compensation first, our analysis shows that the salary component is less, at US$645k.
On examining similar-sized companies in the industry with market capitalizations between US$4.0b and US$12b, we discovered that the median CEO total compensation of that group was US$6.3m. So it looks like Blueprint Medicines compensates Jeff Albers in line with the median for the industry. Moreover, Jeff Albers also holds US$8.1m worth of Blueprint Medicines stock directly under their own name, which reveals to us that they have a significant personal stake in the company.
Speaking on an industry level, nearly 20% of total compensation represents salary, while the remainder of 80% is other remuneration. Blueprint Medicines sets aside a smaller share of compensation for salary, in comparison to the overall industry. If non-salary compensation dominates total pay, it's an indicator that the executive's salary is tied to company performance.
Blueprint Medicines Corporation's Growth
Over the past three years, Blueprint Medicines Corporation has seen its earnings per share (EPS) grow by 52% per year. It achieved revenue growth of 1,025% over the last year.
Overall this is a positive result for shareholders, showing that the company has improved in recent years. The combination of strong revenue growth with medium-term EPS improvement certainly points to the kind of growth we like to see. Historical performance can sometimes be a good indicator on what's coming up next but if you want to peer into the company's future you might be interested in this free visualization of analyst forecasts.
Has Blueprint Medicines Corporation Been A Good Investment?
Blueprint Medicines Corporation has served shareholders reasonably well, with a total return of 15% over three years. But they would probably prefer not to see CEO compensation far in excess of the median.
The company's decent performance might have made most shareholders happy, possibly making CEO remuneration the least of the concerns to be discussed in the upcoming AGM. Despite the pleasing results, we still think that any proposed increases to CEO compensation will be examined based on a case by case basis and linked to performance outcomes.
While CEO pay is an important factor to be aware of, there are other areas that investors should be mindful of as well. We did our research and spotted 2 warning signs for Blueprint Medicines that investors should look into moving forward.
Of course, you might find a fantastic investment by looking at a different set of stocks. So take a peek at this free list of interesting companies.
When trading Blueprint Medicines or any other investment, use the platform considered by many to be the Professional's Gateway to the Worlds Market, Interactive Brokers. You get the lowest-cost* trading on stocks, options, futures, forex, bonds and funds worldwide from a single integrated account. Promoted
This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.